Table 1 Correlation between ANLN expression and clinicopathological characteristics
Cohort I | Cohort II | |||||
|---|---|---|---|---|---|---|
Characteristic | Low ANLN NF n (%) | High ANLN NF n (%) | p-value | Low ANLN NF n (%) | High ANLN NF n (%) | p-value |
Age (years) | ||||||
≤ median | 42 (67.7) | 20 (32.3) | 138 (68.0) | 65 (32.0) | ||
> median | 32 (50.0) | 32 (50.0) | 0.043 | 110 (71.0) | 45 (29.0) | 0.544 |
Tumor size (mm) | ||||||
≤ 20 | 42 (72.4) | 16 (27.6) | 99 (76.7) | 30 (23.3) | ||
> 20 | 32 (47.1) | 36 (52.9) | 0.004 | 149 (65.1) | 80 (34.9) | 0.021 |
ER status | ||||||
Negative | 6 (31.6) | 13 (68.4) | 50 (43.9) | 64 (56.1) | ||
Positive | 68 (63.6) | 39 (36.4) | 0.009 | 191 (81.6) | 43 (18.4) | <0.001 |
PR status | ||||||
Negative | 15 (39.5) | 23 (60.5) | 46 (40.7) | 67 (59.3) | ||
Positive | 59 (67.0) | 29 (33.0) | 0.004 | 188 (82.5) | 40 (17.5) | <0.001 |
Grade (NHG) | ||||||
I | 16 (100.0) | 0 (0.0) | 36 (97.3) | 1 (2.7) | ||
II | 43 (74.1) | 15 (25.9) | 130 (86.7) | 20 (13.3) | ||
III | 15 (28.8) | 37 (71.2) | <0.001 | 76 (47.2) | 85 (52.8) | <0.001 |
Nodal status | ||||||
Negative | 41 (63.1) | 24 (36.9) | 64 (66.0) | 33 (34.0) | ||
Positive | 25 (49.0) | 26 (51.0) | 0.129 | 183 (70.4) | 77 (29.6) | 0.423 |
Ki-67 | ||||||
≤ 10% | 50 (96.2) | 2 (3.8) | 101 (91.8) | 9 (8.2) | ||
> 10% | 22 (30.6) | 50 (69.4) | <0.001 | 142 (59.4) | 97 (40.6) | <0.001 |
HER2 status | ||||||
0–2+ | 72 (61.5) | 45 (38.5) | 193 (70.4) | 81 (29.6) | ||
3+ | 2 (22.2) | 7 (77.8) | 0.021 | 28 (58.3) | 20 (41.7) | 0.095 |